Ocular Therapeutix

Yahoo Finance • 11 days ago

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors

Key Points Saturn V sold 1,504,880 shares of Ocular Therapeutix in the first quarter; the estimated transaction value was $14.34 million. Meanwhile, the quarter-end position value declined by $18.27 million, reflecting both share sales an... Full story

Yahoo Finance • 16 days ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has grant... Full story

Yahoo Finance • last month

Ocular Therapeutix Inc. (OCUL) Appears Highly Attractive Following SOL-1 Clinical Trial Data

Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the 10 best biotech stocks with highest upside potential. On April 13, William Blair maintained an Outperform rating on Ocular Therapeutix (NASDAQ:OCUL) right after the presentation of addit... Full story

Yahoo Finance • last month

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

BEDFORD, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced plans to host an Investor Day on... Full story

Yahoo Finance • 2 months ago

1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have outperformed the market lately as the 1.1% drawdown for healthcare stocks over the p... Full story

Yahoo Finance • 2 months ago

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools

Key Points VR Adviser, LLC added 1,000,000 shares of Spyre Therapeutics; estimated trade size is $25.78 million (based on quarterly average pricing). The quarter-end value of the position increased by $75.73 million, reflecting both tradi... Full story

Yahoo Finance • 2 months ago

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down

On February 17, 2026, VR Adviser, LLC disclosed in a U.S. Securities and Exchange Commission filing that it sold 5,845,915 shares of Ocular Therapeutix(NASDAQ:OCUL), an estimated $71.01 million trade based on quarterly average pricing. VR... Full story

Yahoo Finance • 3 months ago

3 of Wall Street’s Favorite Stocks We’re Skeptical Of

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about com... Full story

Yahoo Finance • 3 months ago

Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory

We came across a bullish thesis on Ocular Therapeutix, Inc. on r/Valueinvesting by Senior-Preference678. In this article, we will summarize the bulls’ thesis on OCUL. Ocular Therapeutix, Inc.'s share was trading at $8.88 as of February 16t... Full story

Yahoo Finance • 3 months ago

Ocular Therapeutix (OCUL) Stock Trades Down, Here Is Why

What Happened? Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) fell 8.6% in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price press... Full story

Yahoo Finance • 3 months ago

Ocular drops after late-stage trial data for wet AMD therapy

[An arrow pointing downwards on top of a pile of US dollar bills.] Ocular Therapeutix (OCUL [https://seekingalpha.com/symbol/OCUL]) lost ~22% in the premarket on Tuesday after the company released data from a late-stage trial evaluating A... Full story

Yahoo Finance • 3 months ago

Biggest stock movers Tuesday: ZIM, CMPS, and more

[Technical Price Chart Data Analysis Showing 2020 Corona Virus Covid-19 Stock Market Crash] Stock futures dipped Tuesday morning amid a holiday-shortened trading week, spotlighting key economic data and corporate earnings ahead. Here are... Full story

Yahoo Finance • 3 months ago

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NA... Full story

Yahoo Finance • 4 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it h... Full story

Yahoo Finance • 5 months ago

BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD

Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the low priced stocks to buy with high upside potential. On December 12, Bank of America raised the firm’s price target on Ocular Therapeutix to $21 from $18 and maintained a Buy rating on th... Full story

Yahoo Finance • 6 months ago

Healthcare Names Post Strong After-Hours Moves: KYMR, OCUL, POAI Among Top Gainers

(RTTNews) - Several healthcare and biotech names posted notable gains in Friday's after-hours trading session, with momentum driven by clinical updates, recent announcements, and technical rebounds. Kymera Therapeutics Inc. (KYMR) surged... Full story

Yahoo Finance • 8 months ago

Ocular Therapeutix prices $475M stock offering

* Ocular Therapeutix (NASDAQ:OCUL [https://seekingalpha.com/symbol/OCUL]) has priced an offering of 37.9M shares at $12.53 each, aiming to raise gross proceeds of around $475.0 million. * The offering is expected to close on or about O... Full story

Yahoo Finance • 8 months ago

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq: OCUL) (“Ocular”, the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced the pricing of a... Full story

Yahoo Finance • 8 months ago

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals observed to date; topline data on track for 1Q 2026 Event to detail how robust SOL-R patient s... Full story

Yahoo Finance • 9 months ago

Key deals this week: Ocular Therapeutix, CoreWeave, Air Lease, Cadence and more

Here's a list of key deals reported across sectors this week: Ocular Therapeutix (NASDAQ:OCUL [https://seekingalpha.com/symbol/OCUL]) rose 6% amid takeover [https://seekingalpha.com/news/4492779-ocular-therapeutix-gains-amid-takeover-spec... Full story